Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27643466 | 0.85 | NOTUM (0.55) | NOTUMSMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL10203776 | 0.84 | NOTUM (0.58) | NOTUMSMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL4553227 | 0.84 | NOTUM (0.54) | NOTUMSMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL10165554 | 0.82 | NOTUM (0.53) | NOTUMSMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL11978597 | 0.82 | KDM4E (0.50) | NOTUMSMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL11978607 | 0.81 | NOTUM (0.47) | NOTUMSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL10203615 | 0.81 | NOTUM (0.51) | NOTUMSMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL11978595 | 0.79 | SMN1; SMN2 (0.36) | SMN1; SMN2MAPTTSHRALDH1A1RIPK1 | |
| SCHEMBL10165389 | 0.79 | NOTUM (0.47) | NOTUMMAPTKMT2AALDH1A1LMNA | |
| SCHEMBL31677529 | 0.78 | SMN1; SMN2 (0.51) | NOTUMSMN1; SMN2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883766-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-16 | — | — | US | disclosed |
| US-8193194-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
| US-20080293737-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1G, CACNA1C, CACNA1B | NOTUM 1907/4885SMN1; SMN2 1767/4885MAPT 2165/4885 |
| US-20080293737-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1G, CACNA1C, CACNA1B | NOTUM 1907/4885SMN1; SMN2 1767/4885MAPT 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.